本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 证券代码：002688 证券简称：金河生物 公告编号：2025-015 金河生物科技股份有限公司 第六届董事会第二十四次会议决议公告 金河生物科技股份有限公司（以下简称"公司"）第六届董事会第二十四次 会议于 2025 年 4 月 9 日以电子邮件方式发出通知，并于 2025 年 4 月 18 日以通 讯方式召开，会议由董事长王东晓先生主持，应到董事 9 人，实到董事 9 人，本 次董事会出席会议董事人数符合法律法规，会议合法有效。会议召开符合《中华 人民共和国公司法》等法律、法规和《公司章程》的规定。与会董事以通讯表决 的方式审议通过了以下议案： 一、以 9 票同意，0 票反对，0 票弃权审议通过了《关于变更公司注册资本 及修订<公司章程>部分条款的议案》。 本议案需提交 2025 年第二次临时股东大会审议。 具体内容详见公司同日于巨潮资讯网（http://www.cninfo.com.cn）及《证 券时报》、《中国证券报》、《证券日报》和《上海证券报》披露的《关于变更 公司注册资本及修订<公司章程 ...

金河生物科技股份有限公司章程 金河生物科技股份有限公司 章 程 （二〇二五年四月修订） | 第一章 总则 3 | | --- | | 第二章 经营宗旨和范围 4 | | 第三章 股份 4 | | 第一节 股份发行 4 | | 第二节 股份增减和回购 7 | | 第三节 股份转让 8 | | 第四章 股东和股东大会 9 | | 第一节 股东 9 | | 第二节 股东大会的一般规定 11 | | 第三节 股东大会的召集 14 | | 第四节 股东大会的提案与通知 15 | | 第五节 股东大会的召开 17 | | 第六节 股东大会的表决和决议 19 | | 第五章 董事会 24 | | 第一节 董事 24 | | 第二节 董事会 27 | | 第六章 总经理及其他高级管理人员 31 | | 第七章 监事会 32 | | 第一节 监事 32 | | 第二节 监事会 33 | | 第八章 财务会计制度、利润分配和审计 34 | | 第一节 财务会计制度 34 | | 第二节 内部审计 37 | | 第三节 会计师事务所的聘任 37 | | 第九章 通知和公告 38 | | 第一节 通知 38 | | 第二节 公告 3 ...

这几只票暗盘资金正在偷偷流入，立即查看>> 养殖业板块震荡走低，金河生物（002688）跌超9%，晓鸣股份（300967）、回盛生物（300871）、华 英农业（002321）、罗牛山（000735）、神农集团（605296）等跟跌。 ...

Group 1 - The aquaculture sector continues to decline, with Jinhe Biology (002688) nearing a trading halt [1] - Other companies such as Xiangjia Co., Ltd. (002982), Xiaoming Co., Ltd. (300967), Fucheng Co., Ltd. (600965), and Huaying Agriculture (002321) are also experiencing declines [1] - Dark pool funds are flowing into these stocks, indicating potential interest from institutional investors [1]

证券代码：002688 证券简称：金河生物 公告编号：2025-014 金河生物科技股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 一、股票交易异常波动的情况介绍 金河生物科技股份有限公司（以下简称"公司"）股票（股票简称：金河生 物，股票代码：002688）交易价格于2025年4月8日、4月9日、4月10日连续三个 交易日收盘价格涨幅偏离值累计25.05%，根据深圳证券交易所的相关规定，属于 股票交易的异常波动情形。 二、公司关注并核实的情况 四、公司认为必要的风险提示 针对公司股票交易异常波动的情况，公司董事会就相关事项进行了自查，并 向控股股东、实际控制人及其一致行动人进行了核实，现就有关情况说明如下： 1、公司前期所披露的信息，不存在需要更正、补充之处。 2、公司未发现近期公共媒体报道了可能或已经对公司股票交易价格产生较 大影响的未公开重大信息。 3、近期公司经营情况及内外部经营环境未发生重大变化。 4、公司、控股股东和实际控制人不存在关于公司的应披露而未披露的重大 事项，或处于筹划阶段的重大事项。 ...

Investment Rating - The report assigns a "Buy" investment rating for the company, indicating a positive outlook for its stock performance in the next 12 months [9]. Core Viewpoints - The ongoing US-China trade tariff disputes have created opportunities for price increases in the company's main product, chlortetracycline, leading to both volume and price growth [2]. - The company holds a dominant position in the global chlortetracycline market, with a production capacity of 55,000 tons, accounting for approximately 50% of global capacity [2]. - The company is expected to benefit from a significant increase in sales in the US market, with a projected revenue growth of 32% year-on-year for its US subsidiary in the first three quarters of 2024 [2]. - The company plans to expand its product offerings, including a new chlortetracycline premix for sheep, which is expected to add over 20,000 tons in sales volume [3]. - The company has initiated a new production project that will add 60,000 tons of veterinary chemical capacity, further enhancing its growth potential [3]. - The company's vaccine business is also expected to grow, with a 3.75% increase in domestic vaccine revenue and an 18.29% increase in the US market [7]. - The environmental business segment is showing steady growth, with a 13.71% increase in revenue in the first half of 2024, contributing positively to overall profitability [8]. - Revenue forecasts for the company are projected to be 2.364 billion, 2.836 billion, and 3.398 billion yuan for 2024, 2025, and 2026 respectively, with corresponding EPS of 0.19, 0.26, and 0.39 yuan [11]. Summary by Sections Market Dynamics - The US has imposed a total tariff increase of 104% on Chinese goods, which has implications for the company's export pricing strategy [1]. - The company is leveraging its market position to implement price increases for its chlortetracycline products in the US market [2]. Product Development - The company is expanding its product line with new veterinary vaccines and chlortetracycline products, which are expected to drive future revenue growth [7][3]. - The introduction of a new brucellosis vaccine is anticipated to become a core product in the vaccine segment [7]. Financial Performance - The company is projected to see significant revenue growth driven by its chlortetracycline and vaccine businesses, alongside its environmental segment [9][11]. - The forecasted growth rates for revenue and net profit indicate a strong upward trend, with net profit expected to grow by 68.5% in 2024 [11].

Investment Rating - The report assigns a "Buy" investment rating for the company, indicating a positive outlook for its stock performance in the next 12 months [9]. Core Views - The ongoing US-China trade tariff disputes have created opportunities for price increases in the company's main product, chlortetracycline, leading to both volume and price growth [2]. - The company holds a dominant position in the global chlortetracycline market, with a production capacity of 55,000 tons, accounting for approximately 50% of global capacity [2]. - The company is expected to benefit from the high demand for chlortetracycline in the US market, where it plans to raise prices due to the lack of local competitors [2]. - The company is expanding its product offerings, including the introduction of new products such as sheep chlortetracycline premix, which is expected to contribute significantly to sales growth [3]. - The company's environmental business is also showing steady growth, with a reported revenue increase of 13.71% in the first half of 2024 [8]. Summary by Sections Market Dynamics - The US has imposed a total tariff increase of 104% on Chinese goods, which has implications for the company's export pricing strategy [1]. - The company is leveraging its market position to implement price increases for its chlortetracycline products in response to the tariffs [2]. Financial Performance - The company forecasts revenues of 2.364 billion, 2.836 billion, and 3.398 billion yuan for 2024, 2025, and 2026 respectively, with corresponding EPS of 0.19, 0.26, and 0.39 yuan [9][11]. - The company expects a significant increase in net profit, projecting growth rates of 68.5% in 2024 and 38.9% in 2025 [11]. Product Development - The company is actively expanding its product line, with new vaccines and chlortetracycline products set to launch in 2025, which are anticipated to enhance revenue streams [7]. - The introduction of a new brucellosis vaccine is expected to become a core product for the company, contributing to its vaccine segment growth [7]. Operational Capacity - The company has initiated a new production project that will add 60,000 tons of veterinary chemical capacity, further supporting its growth strategy [3].

证券代码：002688 证券简称：金河生物 公告编号：2025-013 金河生物科技股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 一、股票交易异常波动的情况介绍 金河生物科技股份有限公司（以下简称"公司"）股票（股票简称：金河生 物，股票代码：002688）交易价格于2025年4月7日1个交易日收盘价格涨幅偏离 值达到20.73%，根据深圳证券交易所的相关规定，属于股票交易的异常波动情形。 二、公司关注并核实的情况 针对公司股票交易异常波动的情况，公司董事会就相关事项进行了自查，并 向控股股东、实际控制人及其一致行动人进行了核实，现就有关情况说明如下： 1、公司前期所披露的信息，不存在需要更正、补充之处。 2、公司未发现近期公共媒体报道了可能或已经对公司股票交易价格产生较 大影响的未公开重大信息。 4、公司、控股股东和实际控制人不存在关于公司的应披露而未披露的重大 事项，或处于筹划阶段的重大事项。在股票异常波动期间，公司控股股东、实际 控制人不存在买卖公司股票的行为。 三、是否存在应披露而未披露信息的说明 ...

Group 1 - The article highlights the significant impact of tariffs on the global market, leading to widespread declines in A-shares, with 5,211 stocks falling and 1,448 hitting the daily limit down [1] - Amidst the market downturn, only a few concept stocks related to export countermeasures and domestic substitution showed resilience [1] Group 2 - Jinhe Biological has achieved a limit-up increase, marking its fourth limit-up in seven days, with a stock price of 6.53 yuan per share and a total market capitalization of 5.038 billion yuan [2] - The trading volume for the limit-up was 131 million yuan, with the highest order amounting to 3.114 billion yuan [2] Group 3 - Other stocks related to Jinhe Biological's product, such as Meino Biological and Weilan Biological, also experienced gains, with Meino achieving two consecutive limit-ups and Weilan reaching a limit-up at one point [3] Group 4 - In response to the high tariffs imposed by the U.S. government, Jinhe Biological announced plans to increase the sales price of its premixed products in the U.S. market to ensure product quality and service, aiming for greater profit margins [4] - Jinhe Biological is a major global supplier of the antibiotic product, with the U.S. being a significant market that relies heavily on imports, as it has no large-scale domestic manufacturers [5] Group 5 - Jinhe Biological holds a strong market position with an annual production capacity of 55,000 tons and a global market share of approximately 50%, allowing it to leverage pricing power to enhance profits [5] - The company is expected to benefit from the tariff increase, which could lead to high revenue growth [5] Group 6 - After three years of decline, Jinhe Biological's performance has improved over the past two years, with net profits showing a positive trend in 2023 [6] - In the first three quarters of the previous year, the company reported revenue of 1.657 billion yuan, a year-on-year increase of 5.57%, and a net profit of 114 million yuan, up 10.38% [7] Group 7 - The company is projected to release its annual report for 2024 and the first quarter of 2025 on April 26 [7] - Future performance is expected to improve due to increased penetration of chemical products and the gradual release of vaccine products, with projected EPS for 2025 and 2026 being 0.24 yuan and 0.30 yuan, respectively [7]

Group 1 - The stock of Jinhe Biological has experienced a significant increase, with 4 limit-up days within 7 trading days, resulting in a cumulative increase of 36.90% and a turnover rate of 48.04% [1] - As of 9:27, the stock's trading volume reached 4.9443 million shares, with a transaction amount of 32.286 million yuan, and a turnover rate of 0.66% [1] - The latest total market capitalization of A-shares is 5.039 billion yuan, while the circulating market capitalization is 4.865 billion yuan [1] Group 2 - According to the latest data from the Longhu list, the stock was listed once due to a cumulative deviation of 20% in the increase over three consecutive trading days, with institutional net selling of 16.0801 million yuan and a total net buying of 71.4341 million yuan from brokerage seats [1] - The company's Q3 report for 2024 shows total operating revenue of 1.657 billion yuan for the first three quarters, representing a year-on-year increase of 5.57%, and a net profit of 114 million yuan, up 10.38% year-on-year [1] Group 3 - The stock's daily performance over the past week includes notable fluctuations, with a peak increase of 10.00% on April 3, 2025, and a significant net inflow of 109.6897 million yuan on the same day [1] - The trading data indicates a mix of gains and losses, with the stock experiencing a decline of 5.60% on March 31, 2025, and a net outflow of 3.10369 million yuan [1]